Who are Ado-trastuzumab emtamsine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NERATINIB, Herceptin, Herceptin, Disitamab vedotin, PTH followed by dose dense AC of FEC, trastuzumab (H).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ado-trastuzumab-emtamsine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ado-trastuzumab emtamsine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ado-trastuzumab emtamsine (Ado-trastuzumab emtamsine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2-targeting antibody-drug conjugate. Area: Oncology.

phase 2 HER2-targeting antibody-drug conjugate HER2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ado-trastuzumab emtamsine (Ado-trastuzumab emtamsine) — Hoffmann-La Roche. Ado-trastuzumab emtansine is a HER2-targeting antibody-drug conjugate that delivers a cytotoxic agent to HER2-positive cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ado-trastuzumab emtamsine TARGET	Ado-trastuzumab emtamsine	Hoffmann-La Roche	phase 2	HER2-targeting antibody-drug conjugate	HER2
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
Herceptin	trastuzumab	Roche	marketed	Antibody-drug conjugate (ADC)	HER2 receptor, subdomain IV	1998-01-01
Herceptin	Trastuzumab-Qyyp	Roche	marketed	HER2/neu receptor antagonist monoclonal antibody	HER2 (c-erbB2) proto-oncogene transmembrane receptor protein	1998-01-01
Disitamab vedotin	disitamab-vedotin	Pfizer	marketed	antibody-drug conjugate	human epidermal growth factor receptor 2 (HER2)
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)
trastuzumab (H)	trastuzumab (H)	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	marketed	HER2-targeted monoclonal antibody	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2-targeting antibody-drug conjugate class)

GI Innovation, Inc. · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Shanghai Miracogen Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ado-trastuzumab emtamsine — Competitive Intelligence Brief. https://druglandscape.com/ci/ado-trastuzumab-emtamsine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab